Cancer Pain Physician Awareness and Novel Drug Delivery

Introduction

Cancer pain can be associated with the cancer itself or with conventional cancer treatments such as chemotherapy or surgery, and it affects over 3 million people in the US alone. Currently, there is a vast range of drugs used in the treatment of cancer pain including opioids, NSAIDs, antidepressants and anticonvulsants, yet most physicians consider morphine to be the current gold standard. 

Scope

Key data and detailed analysis of the 7 leading pharmaceutical markets: the US, Japan, Germany, France, Italy, Spain, and the UK 

In-depth analysis of presentation rates, diagnosis and referral patterns of cancer pain 

Detailed examination of first, second and third line therapies for the treatment of mild, moderate and severe cancer pain 

Investigation of the treatment of breakthrough pain 

Report Highlights

Cancer pain affects over three million people in the US alone, yet despite the availability of a wide range of analgesics and published treatment guidelines, many patients still receive inadequate pain management 

Increased education and awareness of cancer pain and its management among physicians and patients is of critical importance in improving treatment outcomes 

Reasons to Purchase

Identify commercial opportunities from an understanding of the prevalence of cancer pain in the seven major pharmaceutical markets 

Exploit the opportunity to play a pivotal role in promoting effective pain management by providing increased patient and physician education 

Identify first, second and third-line preferred therapies for cancer pain, and the novel non-invasive formulations of breakthrough pain analgesics 

Publisher: Datamonitor Oncology Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Oncology.html#a268